May 31st 2025
After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
FDA Approves Polatuzumab Vedotin/R-CHP Combo in Previously Untreated DLBCL
April 19th 2023Patients with previously untreated diffuse large B-cell lymphoma can now receive polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone following the FDA’s approval of the regimen.
Polatuzumab Vedotin Regimen Yields ‘Meaningful’ Benefit in DLBCL, Expert Says
April 19th 2023Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Real-World Data Highlight Need for Clinically Practical MCL Therapies
April 5th 2023Retrospective data encourage further exploration of non-ASCT regimens in younger patients with mantle cell lymphoma, while maintenance rituximab should be considered following first-line therapy with bendamustine plus rituximab.
FDA Grants Orphan Drug Designation to Tirabrutinib in Primary CNS Lymphoma
March 29th 2023Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.